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ABSTRACT 
The present work describes a validated reverse phase high performance liquid chromatographic method for simultaneous estimation 
of Irbesartan chlorthalidone and cilnidipine in tablet dosage form. The quantification was carried out using C18 column (250 x 
4.6mm, 5μm) and mobile phase comprised of Buffer, Acetonitrile and TEA in a proportion of 80:20:0.1 %v/v/v. The flow rate was 
1.0 ml/min and the eluent was monitored at 222 nm. The selected chromatographic conditions were found to effectively separate 
Irbesartan Chlorthalidone and cilnidipine were 3.807 min, 4.667 min, and 6.887 min respectively. Linearity was found to be in the 
range of 30-90 μg/ml, 1.25-3.75 μg/ml and 1-3 μg/ml for Irbesartan Chlorthalidone and cilnidipine respectively. The percentage 
recoveries of all the drugs were found to be 99.27-99.81%, 99.57-99.99% and 99.22-99.44% for Irbesartan, chlorthalidone, and 
cilnidipine. The proposed method was found to be fast, accurate, precise, and reproducible and can be used for simultaneous 
estimation of these drugs in a tablet. 
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INTRODUCTION  
Irbesartan is an angiotensin converting enzyme blocker 
As with all angiotensin II receptor antagonists, 
irbesartan is indicated for the treatment of hypertension. 
It may also delay progression of diabetic nephropathy 
and is also indicated for the reduction of renal disease 
progression in patients with type 2 diabetes, 
hypertension and microalbuminuria (>30 mg/24 hours) 
or proteinuria (>900 mg/24 hours) 
Chlorthalidone is a diuretic drug used to treat 
hypertension, Compared with other medications of the 
thiazide class, chlortalidone has the longest duration of 
action but a similar diuretic effect at maximal 
therapeutic doses.Chlorthalidone of (RS)-2-Chloro-5-(1-
hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzene-
1-sulfonamide, represents the class of Chlortalidone is a 
diuretic drug used to treat hypertension Chlortalidone 
has the longest duration of action but a similar diuretic 
effect at maximal therapeutic doses., used as an 
Antihypertensive agent.
1-2
 Chlorthalidone inhibits 
sodium ion transport across the renal tubular epithelium 
in the cortical diluting segment of the ascending limb of 
the loop of Henle. By increasing the delivery of sodium 
to the distal renal tubule, Chlorthalidone indirectly 
increases potassium excretion via the sodium-potassium 
exchange mechanism. The individual and combination 
with other drugs determination of Chlorthalidone has 
been carried out by UV spectrophotometer 
3
, RP-HPLC 
4-6
 in bulk and solid dosage forms. Cilnidipine of O3-(2-
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methoxyethyl)O5-[(E)-3-phenylprop-2-enyl]2,6-
dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine- 3,5-
dicarboxylate belongs to Anti hypertensive.
7-9
 Literature 
survey revealed that few analytical methods have been 
reported for the estimation of Cilnidipine included RP-
HPLC
10-11
 UV spectrophotometer.
12-13
.Cilnidipine is a 
dual L-/N-type calcium channel protein inhibitor and 
blocker. Cilnidipine has displayed renal and vascular 
protective effects and improved baroreflex sensitivity in 
patients with hypertension. The present work describes a 
validated reverse phase HPLC method for simultaneous 
determination of these drugs in tablets.  
MATERIALS AND METHODS  
Reagents and Chemicals: Irbesartan, chlorthalidone 
and cilnidipine were received as a gift sample from 
Molecule laboratory, Acetonitrile of HPLC grade, 
Triethyl amine of HPLC grade, Water of HPLC grade.  
Instruments and Chromatographic Conditions: LC-
10AT HPLC system was used for method development, 
degradation studies and validation. Data acquisition was 
performed on Spinchrom HPLC software. The 
separation were achieved on C18 (250 × 4.6 mm, 5μm) 
column. The column was maintained at room 
temperature and the eluent was monitored at 222 nm 
using UV detector. The mixture of Potassium 
dihydrogen phosphate buffer 0.05M (pH 3.5): 
Acetonitrile: TEA (80:20:0.1 v/v) at a flow rate of 1.0 
ml/min was used as a mobile phase. The injection 
volume was 20μl. 
Preparation of standard solutions: 
Irbesartan standard stock solution: (600 μg/mL) 
A 60 mg of Irbesartan was weighed and transferred to a 
100 mL volumetric flask. Volume was made up to the 
mark with methanol. 
Cilnidipine standard stock solution: (20 μg/mL) 
A 20 mg of Cilnidipine was weighed and transferred to 
a 100 mL volumetric flask. Volume was made up to the 
mark with methanol. Take 10ml from this solution and 
transferred to 100 mL volumetric flask and volume 
made up to the mark by mobile phase. 
Chlorthalidone standard stock solution: (25 μg/mL) 
A 25 mg of Chlorthalidone was weighed and transferred 
to a 100 mL volumetric flask. Volume was made up to 
the mark with methanol. Take 10ml from this solution 
and transferred to 100 mL volumetric flask and volume 
made up to the mark by mobile phase. 
Preparation of standard solution of mixtures of 
Irbesartan (60 μg/mL),Cilnidipine (2 μg/mL) and 
Chlorthalidone (2.5 μg/mL) 
Take 1 mL from the Irbesartan stock solution, 1mL from 
Cilnidipine stock solution and 1mL from Chlorthalidone 
stock solution and  transferred to 10 mL volumetric 
flask and volume made up to the mark by mobile phase 
which was used in particular trials. 
Preparation of Mobile phase: 
Potassium dihydrogen phosphate buffer 0.05M (pH 3.5): 
Acetonitrile: TEA (80:20:0.1 v/v) 
Preparation of sample solution: 
Take Crushed Tablet   powder  equivalent  to   60  mg  
of  Irbesartan, 2.5 mg Chlorthalidone and 2  mg  of  
Cilnidipine  was  transferred  to  a  100  ml  volumetric  
flask, and made up volume up to the mark with  mobile 
phase. The solution was filtered through whatman filter 
paper no.  42 and first few drops of filtrate were 
discarded. 10 ml of this solution was diluted to 100 ml 
with mobile phase. The solution was injected 20 µl. The 
areas of resulting peak were measured at 222 nm. 
Validation of RP-HPLC method  
1 Linearity 
The  linearity  for  Irbesartan, Cilnidipine and 
Chlorthalidone were  assessed  by  analysis  of  
combined  standard  solution  in  range  of  30-90 μg/ml, 
1-3 μg/ml and 1.25-3.75 μg/ml  respectively, 
5,7.5,10,12.5,15 ml solutions were pipette out from the 
Stock solution of Irbesartan(60 μg/ml), Cilnidipine (2 
μg/ml) and Chlorthalidone (2.5 μg/ml)  and transfer to 
100 ml volumetric flask and make up with mobile phase 
to obtain 30,45,60,75 and 90 μg/ml, 1,1.5,2,2.5 and 3 
μg/ml  and  1.25,1.875,2.5,3.125 and 3.75 μg/ml  for 
Irbesartan, Cilnidipine and Chlorthalidone respectively 
In term of slope, intercept and correlation co-efficient 
value. The graph of peak area obtained verses respective 
concentration was plotted. 
2 Precision  
Results  should  be  expressed  as  Relative  standard  
deviation  (RSD)  or  coefficient  of  variance.   
A. Repeatability   
Standard solution containing Irbesartan (60 μg/ml), 
Cilnidipine (2 μg/ml) and Chlorthalidone (2.5 μg/ml) 
was injected six times and areas of peaks were measured 
and % R.S.D. was calculated. 
B. Intra-day precision   
Standard  solution  containing  (30,60,90 µg/ml)  of 
Irbesartan and  (1,2,3 µg/ml) of Cilnidipine  and  
(1.25,2.5,3.75 μg/ml) of Chlorthalidone were analyzed 
three times on the same day and % R.S.D was 
calculated.   
C. Inter-day precision  
Standard  solution  containing  (30,60,90 µg/ml)  of 
Irbesartan and  (1,2,3 µg/ml) of Cilnidipine  and  
(1.25,2.5,3.75 μg/ml) of Chlorthalidone were analyzed 
three times on the different day and % R.S.D was 
calculated.   
3 Accuracy  
For Irbesartan 
30 µg/ml drug solution was taken in three different flask 
label A, B and C. Spiked 80%, 100%, 120% of standard 
solution in it and diluted up to 10ml. The area of each 
solution peak was measured at 222 nm. The amount of 
Dagariya et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2017; 7(4):88-96                                 
ISSN: 2250-1177                                                                              [90]                                                                            CODEN (USA): JDDTAO 
Irbesartan was calculated at each level and % recoveries 
were computed. 
 
For Cilnidipine   
1 µg/ml drug solution was taken in three different flask 
label A, B and C. Spiked 80%, 100%, 120% of standard 
solution in it and diluted up to 10ml. The area of each 
solution peak was measured at 222 nm. The amount of 
Cilnidipine was calculated at each level and % 
recoveries were computed. 
For Chlorthalidone 
1.25 µg/ml drug solution was taken in three different 
flask label A, B and C. Spiked 80%, 100%, 120% of 
standard solution in it and diluted up to 10ml. The area 
of each solution peak was measured at 222 nm. The 
amount of Chlorthalidone was calculated at each level 
and % recoveries were computed. 
4 LOD and LOQ   
The  LOD  was  estimated  from  the  set  of  3  
calibration  curves  used  to  determination method 
linearity. The LOD may be calculated as,  
 LOD = 3.3 × (SD/Slope)   
Where,   
SD= Standard deviation of Y-intercepts of 3 calibration 
curves.  
Slope = Mean slope of the 3 calibration curves.   
The LOQ was estimated from the set of 3 calibration 
curves used to determine method linearity.  The LOQ 
may be calculated as, 
LOQ = 10 × (SD/Slope)   
Where,   
SD = Standard deviation of Y-intercepts of 3 calibration 
curves.  
Slope = Mean slope of the 3 calibration curves. 
5 Robustness  
Following parameters were changed one by one and 
their effect was observed on system suitability for 
standard preparation.  
1. Flow rate of mobile phase was changed (± 0.2 
ml/min) 0.8 ml/min and 1.2 ml/min. 
2. pH of Mobile phase  was changed ( ± 0.2 )  3.3 and 
3.5. 
3. Ratio of Mobile phase was changed (±2) Buffer: 
Acetonitrile (82:18) and Buffer: Acetonitrile (78:22)
 
RESULT AND DISCUSSION 
Specificity: 
 
Figure 1: Chromatogram of Irbesartan, Chlorthalidone and Cilnidipine standard 
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Figure 2: Chromatogram of Irbesartan, Chlorthalidone and Cilnidipine sample 
 
Figure 3: Chromatogram of Irbesartan, Chlorthalidone and Cilnidipine Blank 
 
The Chromatograms of Irbesartan, Chlorthalidone and 
Cilnidipine standards and Irbesartan, Chlorthalidone 
and Cilnidipine sample show no interference with the 
Chromatogram of Irbesartan, Chlorthalidone and 
Cilnidipine Blank, so the Developed method is 
Specific. 
Linearity and Range  
The  linearity  for  Irbesartan, Cilnidipine and 
Chlorthalidone were  assessed  by  analysis  of  
combined  standard  solution  in  range  of  30-90 
μg/ml,1-3 μg/ml and 1.25-3.75 μg/ml  respectively. 
Correlation co-efficient for calibration curve 
Irbesartan, Cilnidipine and Chlorthalidone was   found   
to   be   0.999 for all of three. 
The regression line equation for Irbesartan, Cilnidipine 
and Chlorthalidone are as following:  
For Irbesartan:  
y = 26.20x - 10.80 and  
For Chlorthalidone:    
y = 311.1x - 5.764 and  
For Cilnidipine  
y = 425.9x - 5.533 
 
 
Table 1: Linearity data for Irbesartan 
 
Table 2: Linearity data for Chlorthalidone 
Sr. No Concentration (µg/ml) Area 
1 1.25 384.037 
2 1.875 574.785 
3 2.5 776.051 
4 3.125 963.331 
5 3.75 1162.027 
 
Table 3: Linearity data for Cilnidipine 
Sr. No Concentration (µg/ml) Area 
1 1 420.91 
2 1.5 630.213 
3 2 851.093 
4 2.5 1056.653 
5 3 1272.432 
 
Sr.No Concentration (µg/ml) Area 
1 30 776.733 
2 45 1162.735 
3 60 1570.086 
4 75 1949.034 
5 90 2348.984 
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Figure 4: Overlay chromatogram of different concentrations of mixtures of Irbesartan, Cilnidipine and 
Chlorthalidone 
 
Figure 5: Calibration Curve of Irbesartan (30-90 μg/ml) 
 
 
Figure 6: Calibration Curve of Chlorthalidone (1.25-
3.75 μg/ml) 
 
 
Figure 7: Calibration Curve of Cilnidipine (1-3 μg/ml) 
Precision  
 I. Repeatability   
The  data  for  repeatability  of  peak  area  measurement  
for  Irbesartan(60 μg/ml), Cilnidipine  (2 μg/ml) and 
Chlorthalidone (2.5 μg/ml),  based  on  six  
measurements  of  same  solution  of  Irbesartan (60 
μg/ml), Cilnidipine  (2 μg/ml) and Chlorthalidone (2.5 
μg/ml) are  depicted in table. The % RSD for Irbesartan, 
Chlorthalidone and Cilnidipine were found to be 0.271, 
0.249 and 0.154 respectively.   
Table 4: Repeatability data for Irbesartan 
Irbesartan 
Sr No. Conc (μg/ml) Area Mean ± S.D (n=6) % R.S.D 
 
 
 
1. 
 
 
 
60 
1565.283  
 
 
1568.45±4.25 
 
 
 
 
0.271 
1563.976 
1566.882 
1570.032 
1568.622 
1575.875 
 
Table 5: Repeatability data for Chlorthalidone 
Chlorthalidone 
Sr No. Conc (μg/ml) Area Mean ± S.D (n=6) % R.S.D 
 
 
 
1. 
 
 
 
2.5 
773.736  
 
 
775.93 ±1.93 
 
 
 
0.249 
 
775.27 
774.495 
776.049 
776.831 
779.169 
 
Table 6: Repeatability data for Cilnidipine 
Cilnidipine 
Sr No. Conc (μg/ml) Area Mean ± S.D (n=6) % R.S.D 
 
 
 
1. 
 
 
 
2 
848.569  
 
 
850.45 ±1.30 
 
 
 
1.153 
850.25 
849.382 
851.102 
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851.945  
851.473 
II. Intraday precision   
The  data  for  intraday  precision  for  Irbesartan, 
Cilnidipine  and Chlorthalidone is  shown  in  table  
6.10. The % R.S.D for Intraday  precision  was  found  
to  be  0.148-0.554  for  Irbesartan and 0.198-0.312 for  
Chlorthalidone and 0.568-1.062 for Cilnidipine.
 
Table 7: Intraday precision data for estimation of Irbesartan 
 Irbesartan 
SR. NO. Conc. 
(µg/ml) 
Area 
Mean ± S.D. (n=3) 
% R.S.D 
1 30 769.78 ± 2.76 0.359 
2 60 1558.92± 2.31 0.148 
3 90 3498.33± 19.38 0.554 
 
Table 8: Intraday precision data for estimation of Chlorthalidone 
 Chlorthalidone 
SR. NO. Conc. 
(µg/ml) 
Area 
Mean ± S.D. (n=3) 
% R.S.D 
1 1.25 381.73 ± 0.76 0.198 
2 2.5 771.40± 1.53 0.200 
3 3.75 1734.56 ± 5.42 0.312 
 
Table 9: Intraday precision data for estimation of Cilnidipine 
 Cilnidipine 
SR. NO. Conc. 
(µg/ml) 
Area 
Mean ± S.D. (n=3) 
% R.S.D 
1 1 416.24 ± 3.80 0.914 
2 2 844.11± 4.80 0.568 
3 3 1886.32 ± 20.03 1.062 
 
III. Interday precision   
The  data  for  intraday  precision  Irbesartan, Cilnidipine  and Chlorthalidone is  shown  in  table  5.11. The % RSD for 
interday precision was found to be 0.236-0.978 for   Irbesartan and 0.198-0.805 for Chlorthalidone and 0.384-1.029 for 
Cilnidipine   
..         Table 10: Interday precision data for estimation of Irbesartan 
 Irbesartan 
SR. NO. Conc. 
(µg/ml) 
Area 
Mean ± S.D. (n=3) 
% R.S.D 
1 30 769.55 ± 1.82 0.236 
2 60 1544.75± 15.12 0.979 
3 90 3502.97± 8.83 0.252 
 
Table 11: Interday precision data for estimation of Chlorthalidone 
 Chlorthalidone 
SR. NO. Conc. 
(µg/ml) 
Area 
Mean ± S.D. (n=3) 
% R.S.D 
1 1.25 381.36 ± 0.76 0.199 
2 2.5 768.07± 5.82 0.757 
3 3.75 1723.19 ± 13.88 0.806 
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Table 12: Interday precision data for estimation of Cilnidipine 
 Cilnidipine 
SR. NO. Conc. 
(µg/ml) 
Area 
Mean ± S.D. (n=3) 
% R.S.D 
1 1 416.99 ± 1.60 0.385 
2 2 843.80± 4.56 0.540 
3 3 1886.90 ± 19.43 1.29 
 
Accuracy: 
Accuracy of the method was confirmed by recovery study from marketed formulation at three level of standard 
addition.  The results are shown in table 6.12 and 6.13. Percentage recovery for Irbesartan was 99.27-99.81 % and   
Chlorthalidone, it was found to be in range of 99.57-99.99% and for Cilnidipine 99.22-99.44% 
Table 13: Recovery data for Irbesartan 
 
 
SR. NO. 
Conc. 
Level (%) 
Sample 
amount 
(μg/ml) 
 
Amount 
Added 
(μg/ml) 
Amount 
recovered 
(μg/ml) 
% 
Recovery 
% Mean 
Recovery ± S.D 
1 80 % 30 24 23.560 98.17 99.81 ± 1.48 
2 30 24 24.245 101.02 
3 30 24 24.059 100.24 
4 100 % 30 30 29.406 98.02 99.27 ± 1.09 
5 30 30 30.027 100.09 
6 30 30 29.909 99.70 
7 120 % 30 36 35.941 99.83 99.57 ± 0.38 
8 30 36 35.687 99.13 
9 30 36 35.910 99.75 
 
Table 14: Recovery data for Chlorthalidone 
 
 
SR. NO. 
Conc. 
Level (%) 
Sample 
Amount 
 
Amount 
Added 
Amount 
recovered 
(μg/ml) 
% 
Recovery 
% Mean 
Recovery ± S.D 
1 80 % 1.25 1 0.988 98.77 99.99 ± 1.12 
2 1.25 1 1.010 100.99 
3 1.25 1 1.002 100.22 
4 100 % 1.25 1.25 1.237 98.97 99.57 ± 0.56 
5 1.25 1.25 1.251 100.07 
6 1.25 1.25 1.246 99.67 
7 120 % 1.25 1.5 1.504 100.28 99.70 ± 0.59 
8 1.25 1.5 1.487 99.10 
9 1.25 1.5 1.496 99.72 
 
Table 15: Recovery data for Cilnidipine 
 
 
SR. NO. 
Conc. 
Level (%) 
Sample 
Amount 
Amount 
Added 
Amount 
recovered 
(μg/ml) 
% 
Recovery 
% Mean 
Recovery ± S.D 
1 80 % 1 0.8 0.791 98.88 99.41 ± 0.80 
2 1 0.8 0.792 99.03 
3 1 0.8 0.803 100.33 
4 100 % 1 1 0.991 99.08 99.22 ± 0.51 
5 1 1 0.988 98.79 
6 1 1 0.998 99.79 
7 120 % 1 1.2 1.205 100.41 99.44 ± 1.22 
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LOD and LOQ   
Calibration curve was repeated for five times and the 
standard deviation (SD) of the intercepts was calculated. 
Then LOD and LOQ were calculated as follows: 
LOD = 3.3 * SD/slope of calibration curve   
LOQ = 10 * SD/slope of calibration curve   
Where, SD = Standard deviation of intercepts 
 
Table 16: Limit of Detection data for Irbesartan and Chlorthalidone and Cilnidipine 
Irbesartan Chlorthalidone Cilnidipine 
LOD = 3.3 x (SD / Slope) 
= 3.3 x (26.20/10.80) 
=  0.862 µg/ml 
LOD = 3.3 x (SD / Slope) 
= 3.3 x (311.1/5.764) 
= 0.036 µg/ml 
LOD = 3.3 x (SD / Slope) 
= 3.3 x (425.9/5.533) 
= 0.028 µg/ml 
 
Table 17: Limit of   Quantitation data or Irbesartan and Chlorthalidone and Cilnidipine 
Irbesartan Chlorthalidone Cilnidipine 
LOQ = 10 x (SD / Slope) 
= 10 x (26.20/10.80) 
= 2.612 µg/ml 
LOQ = 10 x ( SD / Slope ) 
= 10 x (311.1/5.764) 
= 0.111 µg/ml 
LOQ = 10 x (SD / Slope) 
= 10 x (425.9/5.533) 
= 0.085 µg/ml 
 
Robustness:  
The effect of changes was found to be within the acceptance criteria as shown in table 6.16 and table 6.17. The % RSD 
should be less than 2%. 
Table 18: Robustness data for Irbesartan 
S N. Area at 
Flow rate 
(- 0.2 ml/min) 
Area at 
Flow rate 
(+ 0.2 ml/min) 
Area at 
pH (-0.2) 
Area at 
pH (+0.2) 
Area at 
Mobile phase (-
2) 
Area at 
Mobile phase 
(+2) 
1 1611.009 1521.656 1597.439 1488.475 1595.100 1520.022 
2 1629.813 1533.886 1612.474 1502.462 1614.094 1533.886 
3 1639.308 1538.695 1623.572 1508.516 1618.700 1544.878 
% R.S.D 0.885 0.574 0.814 0.685 0.777 0.813 
 
Table 19: Robustness data for Chlorthalidone 
S N. Area at 
Flow rate 
(- 0.2 ml/min) 
Area at 
Flow rate 
(+ 0.2 ml/min) 
Area at 
pH (-0.2) 
Area at 
pH (+0.2) 
Area at 
Mobile phase  
(-2) 
Area at 
Mobile phase 
(+2) 
1 800.912 753.540 791.556 738.010 793.148 753.540 
2 805.609 758.188 801.985 742.655 797.837 758.188 
3 810.316 760.536 802.535 747.293 799.419 763.610 
% R.S.D 0.584 0.470 0.775 0.625 0.409 0.665 
 
Table 20: Robustness data for Cilnidipine 
S. N. Area at 
Flow rate 
(- 0.2 ml/min) 
Area at 
Flow rate 
(+ 0.2 ml/min) 
Area at 
pH (-0.2) 
Area at 
pH (+0.2) 
Area at 
Mobile phase (-2) 
Area at 
Mobile 
phase(+2) 
1 878.345 826.448 868.092 809.448 869.840 826.448 
2 871.187 819.804 871.991 805.584 872.866 821.574 
3 888.635 834.112 880.104 819.590 877.463 837.464 
% R.S.D 0.997 0.866 0.702 0.891 0.439 0.983 
 
 
8 1 1.2 1.177 98.08 
9 1 1.2 1.198 99.84 
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Analysis of marketed formulation by developed 
method. 
Applicability  of  the  proposed  method  was  tested  by  
analyzing  the  commercially available  Tablet  
formulation Clindasartan-CH. The results are shown in  
following table. 
 
Table 21: Showing the analysis of marketed formulation by developed method 
Tablet Clindasartan-CH 
mg/Tablet powder Irbesartan (150 mg) Chlorthalidone (6.25 mg) Cilnidipine (5 mg) 
Assay (% of label claim*)  
Mean ± S. D. 
100.05±0.544 101.45±0.313 100.92±0.277 
 
The assay results were comparable to labeled value of 
each drug in Tablet dosage form. These results indicate 
that the developed method is accurate, precise, simple 
and rapid. It can be used in the routine quality control of 
dosage form in industries. 
CONCLUSION  
From the above discussion it can be concluded that the 
proposed method is precise, accurate and stability 
indicating. Results are in good agreement with label 
claim which indicates there is no interference of 
excipients. Therefore the proposed method can be used 
for routine analysis of Irbesartan Chlorthalidone and 
Cilnidipine in combined tablet formulation.  
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